Oppenheimer Reaffirms Outperform Rating for Apellis Pharmaceuticals (NASDAQ:APLS)

Oppenheimer reissued their outperform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. APLS has been the subject of a number of other research reports. Robert W. Baird lowered their price target on Apellis Pharmaceuticals from $115.00 to $70.00 and set an outperform […]

Related Keywords

Canada ,Timothy Eugene Sullivan ,Robertw Baird ,Alec Machiels ,Securities Exchange Commission ,Jpmorgan Chase Co ,Apellis Pharmaceuticals ,Apellis Pharmaceuticals Inc ,Institutional Trading Of Apellis Pharmaceuticals ,Us Bancorp ,Needham Company ,Wealth Management Inc ,Wells Fargo Company ,Analyst Recommendations For Apellis Pharmaceuticals ,Advisors Inc ,News Ratings For Apellis Pharmaceuticals Daily ,Clearstead Advisors ,National Bank ,Apellis Pharmaceuticals Trading ,Free Report ,Moderate Buy ,Get Free Report ,Eugene Sullivan ,Exchange Commission ,Director Alec Machiels ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Reiterated Rating ,Oppenheimer Holdings Inc ,